YM155 Down-regulates Survivin and XIAP, Modulates Autophagy and Induces Autophagy-dependent DNA Damage in Breast Cancer Cells

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2014 Sep 16

PMID 25220225

Citations 50

Authors

S M Cheng

Y C Chang

C Y Liu

J Y C Lee

H H Chan

C W Kuo

K Y Lin

S L Tsai

S H Chen

C F Li

E Leung

J R Kanwar

C C Huang

J Y Chang

C H A Cheung

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The aim of this study was to determine the potency and molecular mechanism of action of YM155, a first-in-class survivin inhibitor that is currently under phase I/II clinical investigations, in various drug-resistant breast cancers including the oestrogen receptor positive (ER(+) ) tamoxifen-resistant breast cancer and the caspase-3-deficient breast cancer.

Experimental Approach: The potency of YM155 in SK-BR-3, MDA-MB-231, MCF7 and its tamoxifen-resistant sublines, TamR6, TamR7, TamR8, TamC3 and TamC6, were determined by MTT assay. Western blot analysis, flow cytometric analysis, reverse transcription-PCR, fluorescent microscopy and comet assay were used to determine the molecular mechanism of action of YM155 in different breast cancer cell lines.

Key Results: YM155 was equally potent towards the parental ER(+) /caspase-3-deficient MCF7 breast cancer cells and its tamoxifen-resistant sublines in vitro. The ER(-) /HER2(+) SK-BR-3 breast cancer cells and the triple-negative/caspase-3-expressing metastatic aggressive MDA-MB-231 breast cancer cells were also sensitive to YM155 with IC50 values in the low nanomolar range. Targeting survivin by YM155 modulated autophagy, induced autophagy-dependent caspase-7 activation and autophagy-dependent DNA damage in breast cancer cells. Interestingly, YM155 also induced XIAP degradation and the degradation of XIAP might play an important role in YM155-induced autophagy in breast cancer cells.

Conclusions And Implications: YM155 is a potent survivin inhibitor that has potential for the management of various breast cancer subtypes regardless of the expression of ER, HER2 and caspase-3. Importantly, this study provides new insights into YM155's molecular mechanism of action and therapeutic potential in the treatment of tamoxifen-resistant breast cancer.

Citing Articles

The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2 cells.

Carlos J, Lima K, Rego E, Costa-Lotufo L, Machado-Neto J Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S217-S227.

PMID: 39261151 PMC: 11726093. DOI: 10.1016/j.htct.2024.05.012.

A comprehensive landscape analysis of autophagy in cancer development and drug resistance.

Li Y, Yin Y, Zhang T, Wang J, Guo Z, Li Y Front Immunol. 2024; 15:1412781.

PMID: 39253092 PMC: 11381251. DOI: 10.3389/fimmu.2024.1412781.

Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.

Hong S, Lee Y, Jang E, Hwang H, Kim E, Son D Int J Mol Sci. 2024; 25(1).

PMID: 38203388 PMC: 10779260. DOI: 10.3390/ijms25010216.

Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.

Cappelli L, Fiore D, Phillip J, Yoffe L, Di Giacomo F, Chiu W Blood. 2022; 141(5):503-518.

PMID: 35981563 PMC: 10082359. DOI: 10.1182/blood.2022015414.

Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells.

Mondal A, Jia D, Bhatt V, Akel M, Roberge J, Guo J Sci Rep. 2022; 12(1):13135.

PMID: 35908087 PMC: 9338953. DOI: 10.1038/s41598-022-17446-y.

References

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M . YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67(17):8014-21. DOI: 10.1158/0008-5472.CAN-07-1343. View

Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A . Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010; 103(1):36-42. PMC: 2905296. DOI: 10.1038/sj.bjc.6605713. View

Speit G, Hartmann A . The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2006; 314:275-86. DOI: 10.1385/1-59259-973-7:275. View

Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S . Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007; 27(4C):2803-8. View

Tao Y, Lu J, Du X, Sun L, Zhao X, Peng L . Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 2012; 12:619. PMC: 3543843. DOI: 10.1186/1471-2407-12-619. View

Korkmaz G, Tekirdag K, Ozturk D, Kosar A, Sezerman O, Gozuacik D . MIR376A is a regulator of starvation-induced autophagy. PLoS One. 2013; 8(12):e82556. PMC: 3864973. DOI: 10.1371/journal.pone.0082556. View

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

Qiang L, Wu C, Ming M, Viollet B, He Y . Autophagy controls p38 activation to promote cell survival under genotoxic stress. J Biol Chem. 2012; 288(3):1603-11. PMC: 3548470. DOI: 10.1074/jbc.M112.415224. View

Yu W, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb B . Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol. 2004; 36(12):2531-40. DOI: 10.1016/j.biocel.2004.05.010. View

10.

Huang C, Chen K, Cheung C, Chang J . Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic Biol Med. 2013; 65:1473-1486. DOI: 10.1016/j.freeradbiomed.2013.07.020. View

11.

Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M . Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009; 27(27):4481-6. DOI: 10.1200/JCO.2008.21.1862. View

12.

Dohi T, Okada K, Xia F, Wilford C, Samuel T, Welsh K . An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004; 279(33):34087-90. DOI: 10.1074/jbc.C400236200. View

13.

Leung E, Kannan N, Krissansen G, Findlay M, Baguley B . MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther. 2010; 9(9):717-24. DOI: 10.4161/cbt.9.9.11432. View

14.

Devarajan E, Sahin A, Chen J, Krishnamurthy R, Aggarwal N, Brun A . Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002; 21(57):8843-51. DOI: 10.1038/sj.onc.1206044. View

15.

Glaros T, Stockwin L, Mullendore M, Smith B, Morrison B, Newton D . The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012; 70(1):207-12. DOI: 10.1007/s00280-012-1868-0. View

16.

Tolcher A, Quinn D, Ferrari A, Ahmann F, Giaccone G, Drake T . A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2011; 23(4):968-73. DOI: 10.1093/annonc/mdr353. View

17.

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A . Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012; 3(2):179-97. PMC: 3388737. View

18.

Alexander S, Benson H, Faccenda E, Pawson A, Sharman J, Spedding M . The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol. 2014; 170(8):1676-705. PMC: 3892291. DOI: 10.1111/bph.12449. View

19.

Pawson A, Sharman J, Benson H, Faccenda E, Alexander S, Buneman O . The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 2013; 42(Database issue):D1098-106. PMC: 3965070. DOI: 10.1093/nar/gkt1143. View

20.

Mizushima N, Levine B, Cuervo A, Klionsky D . Autophagy fights disease through cellular self-digestion. Nature. 2008; 451(7182):1069-75. PMC: 2670399. DOI: 10.1038/nature06639. View